10-Q: PROCEPT BioRobotics Reports Strong Q2 Revenue Growth

PROCEPT BioRobotics Corporation reported significant revenue growth and improved gross margins for the second quarter and first half of 2025, driven by increased system sales and utilization of its BPH treatment technology.

Summary

• Revenue for the three months ended June 30, 2025, increased by 48% to $79.2 million, up from $53.4 million in the prior year period.
• Revenue for the six months ended June 30, 2025, increased by 52% to $148.3 million, compared to $97.9 million in the same period last year.
• Net loss for the three months ended June 30, 2025, improved to $19.6 million from $25.6 million in the prior year.
• Net loss for the six months ended June 30, 2025, improved to $44.3 million from $51.6 million in the prior year.
• Gross margin increased to 65% for both the three and six months ended June 30, 2025, up from 59% and 58% respectively in the prior year periods.
• As of June 30, 2025, the global install base of AquaBeam and HYDROS Robotic Systems reached 762, with 595 systems in the United States.
• Cash and cash equivalents totaled $302.7 million as of June 30, 2025.
• Net cash used in operating activities for the six months ended June 30, 2025, was $32.0 million, an improvement from $48.0 million in the prior year period.
• The company's accumulated deficit reached $590.3 million as of June 30, 2025.

Sentiment

Score: 7

Explanation: The company demonstrates strong operational performance with significant revenue growth and improved gross margins, leading to a reduced net loss. The expansion of its install base and positive regulatory/reimbursement developments are strong indicators of market traction. While still operating at a net loss and burning cash, the positive trends and management's confidence in liquidity for the next 12 months suggest a favorable outlook, albeit with inherent risks of a growth-stage medical device company.

Positives

• Achieved substantial revenue growth of 48% for the quarter and 52% for the six-month period, indicating strong market adoption.
• Improved gross margin to 65%, reflecting increased production volume and better cost management.
• Reduced net loss by $6.0 million for the quarter and $7.2 million for the six-month period, demonstrating progress towards profitability.
• Expanded global install base of robotic systems to 762, with a significant presence in the U.S. (595 systems).
• Received FDA 510(k) clearance for the next-generation HYDROS Robotic System on August 20, 2024.
• Maintained compliance with all debt covenants as of June 30, 2025.
• Secured favorable Medicare coverage decisions, providing access to Aquablation therapy for 100% of eligible Medicare patients.
• Aquablation therapy has been added to clinical guidelines of professional associations, including the American Urological Association, due to strong clinical evidence and KOL support.
• Modified Term Loan Facility repayment terms in August 2025, making the entire principal amount due at the October 2027 maturity date, removing prior monthly amortization payments.

Negatives

• Continued to incur a net loss of $19.6 million for the quarter and $44.3 million for the six-month period.
• Accumulated deficit increased to $590.3 million, indicating ongoing historical losses.
• Cash and cash equivalents decreased from $333.7 million at December 31, 2024, to $302.7 million at June 30, 2025.
• Selling, general and administrative expenses increased significantly by 38% for the quarter and 39% for the six-month period, primarily due to commercial expansion.
• Inventory increased by $10.9 million from December 31, 2024, to June 30, 2025, potentially tying up capital.

Risks

• Future funding requirements are dependent on market acceptance, sales force expansion, clinical trials, regulatory approvals, manufacturing costs, intellectual property defense, potential acquisitions, competing technologies, and international expansion.
• The ability to increase gross margins relies on effectively managing costs and scaling manufacturing operations efficiently.
• Continuous investment in research and development is required for product improvements and the development of additional and next-generation technologies.
• The sale of equity and convertible debt securities in the future may result in dilution to stockholders.
• Debt financing, if available, may involve covenants restricting operations or the ability to incur additional debt.
• Additional financing may not be available at all, or in amounts or on terms unacceptable.
• Inability to obtain additional financing may require delays in the development, commercialization, and marketing of products.
• Litigation can have an adverse impact due to defense and settlement costs, diversion of management resources, negative publicity, and reputation harm.
• Operating in a very competitive and rapidly changing environment, with new risks emerging over time.
• Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, meaning actual results could differ materially.

Future Outlook

Management expects revenue to increase in absolute dollars for the foreseeable future, driven by continued adoption of Aquablation therapy and increased system utilization. Gross margin is anticipated to increase over the long term as production volume grows and fixed manufacturing overhead costs are spread over more units. Research and development expenses are expected to increase in absolute dollars but decrease as a percentage of revenue over time, reflecting strategic investments in product enhancements and next-generation technologies, including the integration of artificial intelligence and machine learning. Selling, general and administrative expenses are also projected to increase in absolute dollars due to commercial infrastructure expansion, but are expected to decrease as a percentage of revenue over time. The company believes its existing cash and cash equivalents, combined with anticipated revenue, will be sufficient to meet capital requirements and fund operations for at least the next twelve months.

Management Comments

• "We believe that Aquablation therapy represents a paradigm shift in the surgical treatment of BPH by addressing compromises associated with alternative surgical interventions."
• "We designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that is independent of prostate size and shape, and delivers resection independent of surgeon experience."
• "We believe that these favorable coverage decisions have been a catalyst for hospital adoption of our robotic systems."
• "We believe our strong body of clinical evidence and support from key societies, supplemented by the momentum from Medicare coverage, have led to favorable coverage decisions from many large commercial payors."
• "We plan to leverage these successes in our active discussions with commercial payors to establish additional positive national and regional coverage policies."
• "We believe that additional commercial payor coverage will contribute to increasing utilization of our system over time."
• "Our future growth is dependent on these continuous improvements which require significant resources and investment."
• "Based on our operating plan, we currently believe that our existing cash and cash equivalents and anticipated revenue will be sufficient to meet our capital requirements and fund our operations through at least the next twelve months from the issuance date of the financial statements included in the Quarterly Report on Form 10-Q."

Industry Context

The company operates in the surgical robotics and urology sectors, specifically targeting benign prostatic hyperplasia (BPH), a common prostate condition affecting approximately 40 million men in the United States. Its Aquablation therapy, delivered by robotic systems, aims to be a minimally invasive alternative to traditional surgical treatments like transurethral resection of prostate (TURP). The industry is characterized by rapid technological advancements, the critical importance of regulatory approvals (e.g., FDA clearances), and the need for favorable reimbursement policies from third-party payors (Medicare, private insurers) to drive market adoption and commercial success. The company's focus on clinical evidence and professional society endorsements is crucial for establishing its technology as a standard of care in a competitive medical device market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking. However, it highlights that Aquablation therapy demonstrated superior safety and non-inferior efficacy compared to TURP (transurethral resection of prostate), the historical standard of care for BPH, in its U.S. pivotal WATER study. It also showed superior efficacy in a subset of patients with prostates larger than 50 ml. This suggests a strong clinical profile relative to established surgical methods for BPH.

Management Changes

Legal Proceedings

• Not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on the business.

Stakeholder Impact

• Shareholders: Experience potential future dilution if additional equity or debt financing is pursued. Benefit from strong revenue growth and improving financial performance.
• Employees: Expansion of commercial, R&D, and clinical teams suggests job growth opportunities. Reorganization of commercial leadership may impact some personnel.
• Customers (Hospitals/Urologists): Benefit from increased system availability, training, and support, as well as the introduction of the next-generation HYDROS Robotic System.
• Patients: Gain expanded access to Aquablation therapy due to increased system adoption and favorable reimbursement policies, potentially leading to improved treatment outcomes for BPH.
• Creditors: The company is in compliance with all debt covenants, and the modification of loan repayment terms to a single payment at maturity provides clarity on future obligations.

Next Steps

• Continue to increase the direct team of capital sales representatives to drive system placement within hospitals.
• Expand the team of highly trained Aquablation representatives and clinical specialists to drive system utilization.
• Leverage urologists' experiences with Aquablation therapy to capture more surgical volumes and establish it as the surgical standard of care.
• Engage in active discussions with commercial payors to establish additional positive national and regional coverage policies.
• Continue ongoing efforts in key international markets to expand established coverage and further improve patient access to Aquablation therapy.
• Make strategic investments in research and development to develop and enhance existing products and technologies.
• Leverage treatment data and software development capabilities to integrate artificial intelligence and machine learning for computer-assisted anatomy recognition and improved treatment planning and personalization.
• Separate the Chief Commercial Officer role into two new leadership positions: Senior Vice President of Sales and Senior Vice President of Marketing.

Key Dates

Recommendation

The company demonstrates impressive revenue growth and significant improvements in gross margin and net loss, indicating strong operational execution and market acceptance of its robotic systems. The expansion of its install base and favorable reimbursement landscape are positive catalysts. However, the company continues to operate at a net loss and has an increasing accumulated deficit, requiring ongoing cash burn. While management believes current liquidity is sufficient for the next 12 months, future funding needs are acknowledged. The insider trading plans, while compliant, may introduce a degree of caution. Given the strong growth but continued unprofitability, a 'hold' recommendation is appropriate for a seasoned investor, suggesting monitoring for sustained progress towards profitability and efficient cash management.

Keywords

Surgical Robotics, Urology, BPH Treatment, Aquablation Therapy, Medical Devices, Robotic Systems, Healthcare Technology, Minimally Invasive Surgery, Prostate Health, FDA Clearance